Author: Editor-In-Chief
Cursor, an AI-coding startup, is nearing a new round of funding that would bring the four-year-old company to at least $2 billion in new capital, according to four people familiar with the matter. Returning investors Thrive and Andreessen Horowitz are expected to lead the financing at a valuation of $50 billion ahead of the new capital injection, the people said. New investor Battery Ventures may also participate in the financing, two people familiar with the matter said. Strategic investor Nvidia also plans to write a check, one of the people said. Although this round is already full, the terms of…
Thomas Fuller | SOPA Images | Light Rocket | Getty ImagesMidium Shares more than doubled on Thursday after the social media platform provider unexpectedly became the latest company to refocus its efforts on artificial intelligence.The penny stock rose about 130% to more than $3 per share. Mydium, which crossed the $5 milestone at one point during the trading day, rose to its highest price in more than a year and recorded its best day since early 2025.Stock chart iconStock chart iconMidium, 1 dayThe New Jersey-based company announced Wednesday that it will change its name to Myseum.AI as it focuses on…
Kevin Weil, Chief Product Officer at OpenAI, speaks at the Hill & Valley Forum on Wednesday, April 30, 2025, at the U.S. Capitol in Washington, DC, USA. Al Drago | Bloomberg | Getty ImagesTwo OpenAI executives announced their departure from the company on Friday, the latest in a series of leadership shakeups at the artificial intelligence startup. Bill Peebles, who led OpenAI’s defunct short-form video app Sora, and Kevin Weil, vice president of OpenAI for Science, shared news of their departure in separate posts on X on Friday. An OpenAI spokesperson said the company is decentralizing OpenAI for Science to…
tel aviv — The phone call that US President Donald Trump had expected did not materialize, but it left little doubt about what would happen next. On Thursday morning, President Trump said Israeli Prime Minister Benjamin Netanyahu would meet with Lebanese President Joseph Aoun. It was supposed to be the first direct contact between the leaders of neighboring countries with no diplomatic relations in decades. President Trump declared it would provide “a little bit of breathing room.” But Aoun rejected the call against the backdrop of the fierce war between Israel and Iran’s proxy Hezbollah. Trump wasn’t waiting for the…
Bournemouth have reached an agreement to appoint Marco Rose to replace Andoni Iraola at the Vitality Stadium.Rose will officially take over as manager this summer, but after Iraola confirmed his departure from the club, an agreement has been reached allowing both the new manager and the club to plan for next season. Iraola revealed on Tuesday that he will step down as head coach when his contract expires at the end of the season, bringing his three-year reign at the Cherries to an end. Sky Sports News reported that former RB Leipzig manager Rose is the frontrunner to replace Iraola,…
OpenAI is losing two of its most ambitious moonshot architects. Kevin Weil, who led the company’s scientific research initiatives, and Bill Peebles, a researcher behind the AI video tool Sora, both announced their retirements on Friday. The exit comes as OpenAI consolidates around enterprise AI and its upcoming “super apps.” The exit follows OpenAI’s decision to cut back on “side quests,” including bets for customers like Sora and OpenAI for Science. Sora was losing an estimated $1 million a day in computational costs and shut down last month. OpenAI for Science was the internal research group behind Prism, an AI-powered…
Alternative investment giant Apollo Global Management has seen its stock price plummet this year as a result of concerns in the private credit market. On Wednesday at CNBC’s American Investment Forum in Washington, D.C., the company’s billionaire CEO Mark Rowan offered the latest defense of the company’s book of business and the latest attempt to distance it from the riskiest end of the private credit market.Apollo is facing intense scrutiny over its decision to cap quarterly redemptions on its private credit funds at 5%. Although 5% is a generally accepted standard in the industry, other companies in the sector have…
WASHINGTON, DC – US President Donald Trump has posted a series of rapid-fire messages on the US-Israel-Iran war, claiming his government has secured significant concessions ahead of the possibility of another round of cease-fire negotiations.President Trump’s statement posted on Truth Social on Friday claimed that Iran had agreed to open the Strait of Hormuz and “never close it.”Recommended stories list of 3 itemsend of listHe also claimed that Iran would hand over “nuclear dust” and “forbid” Israel from launching an attack on Lebanon.Iran has confirmed it will reopen the Strait of Hormuz during a “period” of the current cessation of…
Conor Benn has signed a multi-fight, multi-year contract with Zuffa Boxing.Ben worked with Zuffa Boxing on its latest bout, a 10-round victory over former two-time world champion Regis Prograis at Tottenham Hotspur Stadium last weekend. This was “The Destroyer’s” third consecutive match on the football field, following two epic battles with Chris Eubank Jr. Twitter This content is provided by Twittercookies and other technologies may be used. To view this content, you must allow cookies. You can change the settings and enable it using the buttons below. Twitter Use cookies or allow them only once. You can change your settings…
Piotr Swat | Light Rocket | Getty ImagesAs the high-margin GLP-1 compounding business evolves, his and her health We may be discovering new opportunities for peptides. Shares of telemedicine companies soared Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. announced Wednesday that the FDA plans to convene a Pharmacy Compounding Advisory Committee meeting to consider peptides for possible inclusion on the 503A bulk list. This list is a designation that allows medicines to be compounded based on individual prescriptions rather than being mass-produced. For Hims, the bigger story is how expanding its peptide formulations can open up…